# SERENA-1 (NCT03616587)

> Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03616587
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: ER+ HER2- Advanced Breast Cancer
- Interventions: AZD9833; AZD9833; AZD9833 with palbociclib; AZD9833 with palbociclib; AZD9833 with everolimus; AZD9833 with everolimus; AZD9833 with abemaciclib; AZD9833 with abemaciclib; AZD9833 with capivasertib; AZD9833 with capivasertib; AZD9833 with ribociclib; AZD9833 with ribociclib; AZD9833 with anastrozole; AZD9833 with anastrozole
- Enrollment: 396
- Primary outcome: The number of subjects with dose-limiting toxicity, as defined in the protocol.
- Primary outcome: The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.

## Commentary we found

- YouTube: 10
- Podcasts: 3
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=serena-1-nct03616587

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03616587", "email": "<work email>"}; the inbox owner confirms by the emailed link.